The agency said it predicts fewer than 500 ALS cases have the gene mutation, SOD1-ALS, which “attacks and kills the nerve cells that control voluntary muscles.”
Qalsody is approved to be administered through spinal injection by healthcare workers who are experienced in the process.
Its approval follows a study that found “nominally significant reductions in plasma [neurofilament light chain] concentration” compared to the placebo group, the FDA said. Neurofilaments are released from damaged neurons and act as a marker for neurodegeneration, meaning the drug could have a clinical benefit, according to Biogen, the ALS drug’s maker.
Biogen is conducting research to confirm the drug’s efficacy because the therapy was approved via the FDA’s accelerated pathway.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
